12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Lucentis ranibizumab: Phase III started

Novartis disclosed in its 4Q10 earnings that in October it began a Phase III trial of Lucentis to treat pathological myopia. Lucentis is approved in the U.S. to treat age-related macular degeneration (AMD) and macular...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >